A Major Step in Transforming Cancer Care
ConcertAI has acquired CancerLinQ, a former subsidiary of the American Society of Clinical Oncology (ASCO). This acquisition promises to significantly enhance cancer care and research through the advancement of precision medicine, acceleration of the application of real-world data for research, and initiation of new clinical trials based on CancerLinQ’s TriaLinQ concepts. ASCO continues its involvement through a strategic collaboration, focusing on CancerLinQ’s growth and its mission.
CancerLinQ is at the forefront of real-world data and quality of care technology, bringing together clinical data from various EMR systems. Its network comprises over 100 cancer organizations, 13 EMR integrations, and data from more than six million patients. This vast dataset is instrumental in identifying trends and improving cancer treatment practices.
Interested in learning more about this groundbreaking venture and its implications for cancer research and patient care? Click the button below to read more!
Read the blog by Jeff Elton, PhD
Leadership’s Viewpoint on Our Joint Venture
Bolstering SmartLinQTM to include new data sources alongside the robust clinical data currently available
%20platform.svg)
Making clinical trials participation more accessible and less burdensome through ConcertAI’s Digital Access to Clinical Trial (DACT) platform
Developing more robust clinical decision support within SmartLinQ
